200 related articles for article (PubMed ID: 26978009)
1. Structural complexes of the agonist, inverse agonist and antagonist bound C5a receptor: insights into pharmacology and signaling.
Rana S; Sahoo AR; Majhi BK
Mol Biosyst; 2016 Apr; 12(5):1586-99. PubMed ID: 26978009
[TBL] [Abstract][Full Text] [Related]
2. The Model Structures of the Complement Component 5a Receptor (C5aR) Bound to the Native and Engineered
Sahoo AR; Mishra R; Rana S
Sci Rep; 2018 Feb; 8(1):2955. PubMed ID: 29440703
[TBL] [Abstract][Full Text] [Related]
3. Orthosteric and allosteric action of the C5a receptor antagonists.
Liu H; Kim HR; Deepak RNVK; Wang L; Chung KY; Fan H; Wei Z; Zhang C
Nat Struct Mol Biol; 2018 Jun; 25(6):472-481. PubMed ID: 29867214
[TBL] [Abstract][Full Text] [Related]
4. Modeling molecular mechanisms of binding of the anaphylatoxin C5a to the C5a receptor.
Nikiforovich GV; Marshall GR; Baranski TJ
Biochemistry; 2008 Mar; 47(10):3117-30. PubMed ID: 18275159
[TBL] [Abstract][Full Text] [Related]
5. Allosterism in human complement component 5a ((h)C5a): a damper of C5a receptor (C5aR) signaling.
Rana S; Sahoo AR; Majhi BK
J Biomol Struct Dyn; 2016 Jun; 34(6):1201-13. PubMed ID: 26212097
[TBL] [Abstract][Full Text] [Related]
6. Model structures of inactive and peptide agonist bound C5aR: Insights into agonist binding, selectivity and activation.
Rana S; Sahoo AR
Biochem Biophys Rep; 2015 May; 1():85-96. PubMed ID: 29124137
[TBL] [Abstract][Full Text] [Related]
7. Submolecular probing of the complement C5a receptor-ligand binding reveals a cooperative two-site binding mechanism.
Dumitru AC; Deepak RNVK; Liu H; Koehler M; Zhang C; Fan H; Alsteens D
Commun Biol; 2020 Dec; 3(1):786. PubMed ID: 33339958
[TBL] [Abstract][Full Text] [Related]
8. Molecular characterization of the gerbil C5a receptor and identification of a transmembrane domain V amino acid that is crucial for small molecule antagonist interaction.
Waters SM; Brodbeck RM; Steflik J; Yu J; Baltazar C; Peck AE; Severance D; Zhang LY; Currie K; Chenard BL; Hutchison AJ; Maynard G; Krause JE
J Biol Chem; 2005 Dec; 280(49):40617-23. PubMed ID: 16230349
[TBL] [Abstract][Full Text] [Related]
9. Transdermal pharmacology of small molecule cyclic C5a antagonists.
Proctor LM; Woodruff TM; Sharma P; Shiels IA; Taylor SM
Adv Exp Med Biol; 2006; 586():329-45. PubMed ID: 16893082
[TBL] [Abstract][Full Text] [Related]
10. Potent cyclic antagonists of the complement C5a receptor on human polymorphonuclear leukocytes. Relationships between structures and activity.
March DR; Proctor LM; Stoermer MJ; Sbaglia R; Abbenante G; Reid RC; Woodruff TM; Wadi K; Paczkowski N; Tyndall JD; Taylor SM; Fairlie DP
Mol Pharmacol; 2004 Apr; 65(4):868-79. PubMed ID: 15044616
[TBL] [Abstract][Full Text] [Related]
11. Site-specific disulfide capture of agonist and antagonist peptides on the C5a receptor.
Buck E; Bourne H; Wells JA
J Biol Chem; 2005 Feb; 280(6):4009-12. PubMed ID: 15550394
[TBL] [Abstract][Full Text] [Related]
12. Identification and characterization of NDT 9513727 [N,N-bis(1,3-benzodioxol-5-ylmethyl)-1-butyl-2,4-diphenyl-1H-imidazole-5-methanamine], a novel, orally bioavailable C5a receptor inverse agonist.
Brodbeck RM; Cortright DN; Kieltyka AP; Yu J; Baltazar CO; Buck ME; Meade R; Maynard GD; Thurkauf A; Chien DS; Hutchison AJ; Krause JE
J Pharmacol Exp Ther; 2008 Dec; 327(3):898-909. PubMed ID: 18753409
[TBL] [Abstract][Full Text] [Related]
13. Structural models for the complex of chemotaxis inhibitory protein of Staphylococcus aureus with the C5a receptor.
Nikiforovich GV; Baranski TJ
Biochem Biophys Res Commun; 2009 Dec; 390(3):481-4. PubMed ID: 19799858
[TBL] [Abstract][Full Text] [Related]
14. The role of the ribosomal protein S19 C-terminus in Gi protein-dependent alternative activation of p38 MAP kinase via the C5a receptor in HMC-1 cells.
Nishiura H; Tokita K; Li Y; Harada K; Woodruff TM; Taylor SM; Nsiama TK; Nishino N; Yamamoto T
Apoptosis; 2010 Aug; 15(8):966-81. PubMed ID: 20473571
[TBL] [Abstract][Full Text] [Related]
15. Residues 10-18 within the C5a receptor N terminus compose a binding domain for chemotaxis inhibitory protein of Staphylococcus aureus.
Postma B; Kleibeuker W; Poppelier MJ; Boonstra M; Van Kessel KP; Van Strijp JA; de Haas CJ
J Biol Chem; 2005 Jan; 280(3):2020-7. PubMed ID: 15542591
[TBL] [Abstract][Full Text] [Related]
16. Structure of the complement C5a receptor bound to the extra-helical antagonist NDT9513727.
Robertson N; Rappas M; Doré AS; Brown J; Bottegoni G; Koglin M; Cansfield J; Jazayeri A; Cooke RM; Marshall FH
Nature; 2018 Jan; 553(7686):111-114. PubMed ID: 29300009
[TBL] [Abstract][Full Text] [Related]
17. C5aR antagonist inhibits occurrence and progression of complement C5a induced inflammatory response of microglial cells through activating p38MAPK and ERK1/2 signaling pathway.
Liu Y; Xu SQ; Long WJ; Zhang XY; Lu HL
Eur Rev Med Pharmacol Sci; 2018 Nov; 22(22):7994-8003. PubMed ID: 30536348
[TBL] [Abstract][Full Text] [Related]
18. Comparative agonist/antagonist responses in mutant human C5a receptors define the ligand binding site.
Higginbottom A; Cain SA; Woodruff TM; Proctor LM; Madala PK; Tyndall JD; Taylor SM; Fairlie DP; Monk PN
J Biol Chem; 2005 May; 280(18):17831-40. PubMed ID: 15661745
[TBL] [Abstract][Full Text] [Related]
19. Negative allosteric modulators of cannabinoid receptor 2: protein modeling, binding site identification and molecular dynamics simulations in the presence of an orthosteric agonist.
Pandey P; Roy KK; Doerksen RJ
J Biomol Struct Dyn; 2020 Jan; 38(1):32-47. PubMed ID: 30652534
[TBL] [Abstract][Full Text] [Related]
20. The role of the ribosomal protein S19 C-terminus in altering the chemotaxis of leucocytes by causing functional differences in the C5a receptor response.
Nishiura H; Zhao R; Yamamoto T
J Biochem; 2011 Sep; 150(3):271-7. PubMed ID: 21613290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
